JAMP Signs an Agreement with Alvotech to Commercialize Five Biosimilars in Canada

 JAMP Signs an Agreement with Alvotech to Commercialize Five Biosimilars in Canada

JAMP Signs an Agreement with Alvotech to Commercialize Five Biosimilars in Canada

Shots:

  • JAMP to get exclusive commercialization right for Alvotech’s five biosimilar therapies, having the market value of ~2B annually in Canada
  • The collaboration allows JAMP to expand its generic portfolio, expected to exceed 500 products by 2022 and now has six biosimilars in its pipeline leading to an improvement in patient access to the therapies
  • The partnership advances Alvotech’s fully integrated value chain from cell line development to commercial manufacturing and allows patients to utilize biosimilars as well as the JAMP care patient support program in Canada

Click here ­to­ read full press release/ article | Ref: Newswire Canada | Image: Hans India

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post